{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:11:16Z","timestamp":1793970676933,"version":"4.8.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"7830","license":[{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2020,10,22]]},"DOI":"10.1038\/s41586-020-2708-8","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T06:04:31Z","timestamp":1598508271000},"page":"560-566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":644,"title":["A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures"],"prefix":"10.1038","volume":"586","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8942-1551","authenticated-orcid":false,"suffix":"III","given":"Kenneth H.","family":"Dinnon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah R.","family":"Leist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4228-2192","authenticated-orcid":false,"given":"Caitlin E.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8012-5302","authenticated-orcid":false,"given":"Stephanie A.","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ande","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Boyd L.","family":"Yount","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8323-7243","authenticated-orcid":false,"given":"Yixuan J.","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7780-9973","authenticated-orcid":false,"given":"Lily E.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra L.","family":"Gully","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane J.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9143-9403","authenticated-orcid":false,"given":"Matthew D.","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid C.","family":"Choong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Glenn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa E.","family":"Gralinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9181-2183","authenticated-orcid":false,"given":"Timothy P.","family":"Sheahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6827-8701","authenticated-orcid":false,"given":"Ralph S.","family":"Baric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,27]]},"reference":[{"key":"2708_CR1","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","volume":"382","author":"Q Li","year":"2020","unstructured":"Li, Q. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Engl. J. Med. 382, 1199\u20131207 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2708_CR2","doi-asserted-by":"publisher","unstructured":"Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine development enabled by prototype pathogen preparedness. Nature https:\/\/doi.org\/10.1038\/s41586-020-2622-0 (2020).","DOI":"10.1038\/s41586-020-2622-0"},{"key":"2708_CR3","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.cell.2020.06.011","volume":"182","author":"AO Hassan","year":"2020","unstructured":"Hassan, A. O. et al. A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies. Cell. 182, 744\u2013753 (2020).","journal-title":"Cell."},{"key":"2708_CR4","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"2708_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.cell.2020.05.042","volume":"182","author":"YJ Hou","year":"2020","unstructured":"Hou, Y. J. et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell 182, 429\u2013446 (2020).","journal-title":"Cell"},{"key":"2708_CR6","doi-asserted-by":"publisher","first-page":"e12465","DOI":"10.15252\/emmm.202012465","volume":"12","author":"E Andreakos","year":"2020","unstructured":"Andreakos, E. & Tsiodras, S. COVID-19: lambda interferon against viral load and hyperinflammation. EMBO Mol. Med. 12, e12465 (2020).","journal-title":"EMBO Mol. Med."},{"key":"2708_CR7","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/cts.12840","volume":"13","author":"R Humeniuk","year":"2020","unstructured":"Humeniuk, R. et al. Safety, tolerability, and pharmacokinetics of remdesivir, an antiviral for treatment of COVID-19, in healthy subjects. Clin. Transl. Sci. 13, 896\u2013906 (2020).","journal-title":"Clin. Transl. Sci."},{"key":"2708_CR8","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.cell.2020.06.011","volume":"182","author":"AO Hassan","year":"2020","unstructured":"Hassan, A. O. et al. A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies. Cell 182, 744\u2013753 (2020).","journal-title":"Cell"},{"key":"2708_CR9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.cell.2020.05.027","volume":"182","author":"RD Jiang","year":"2020","unstructured":"Jiang, R. D. et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell 182, 50\u201358 (2020).","journal-title":"Cell"},{"key":"2708_CR10","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41586-020-2312-y","volume":"583","author":"L Bao","year":"2020","unstructured":"Bao, L. et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 583, 830\u2013833 (2020).","journal-title":"Nature"},{"key":"2708_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.chom.2020.05.020","volume":"28","author":"SH Sun","year":"2020","unstructured":"Sun, S. H. et al. A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe 28, 124\u2013133 (2020).","journal-title":"Cell Host Microbe"},{"key":"2708_CR12","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.cell.2020.06.010","volume":"182","author":"J Sun","year":"2020","unstructured":"Sun, J. et al. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. Cell 182, 734\u2013743 (2020).","journal-title":"Cell"},{"key":"2708_CR13","doi-asserted-by":"publisher","first-page":"e20201241","DOI":"10.1084\/jem.20201241","volume":"217","author":"B Israelow","year":"2020","unstructured":"Israelow, B. et al. Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. J. Exp. Med. 217, e20201241 (2020).","journal-title":"J. Exp. Med."},{"key":"2708_CR14","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.chom.2020.03.023","volume":"27","author":"YI Kim","year":"2020","unstructured":"Kim, Y. I. et al. Infection and rapid transmission of SARS-CoV-2 in ferrets. Cell Host Microbe 27, 704\u2013709 (2020).","journal-title":"Cell Host Microbe"},{"key":"2708_CR15","doi-asserted-by":"publisher","first-page":"16587","DOI":"10.1073\/pnas.2009799117","volume":"117","author":"M Imai","year":"2020","unstructured":"Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl Acad. Sci. USA 117, 16587\u201316595 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2708_CR16","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","volume":"583","author":"SF Sia","year":"2020","unstructured":"Sia, S. F. et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 583, 834\u2013838 (2020).","journal-title":"Nature"},{"key":"2708_CR17","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1126\/science.abb7314","volume":"368","author":"B Rockx","year":"2020","unstructured":"Rockx, B. et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science 368, 1012\u20131015 (2020).","journal-title":"Science"},{"key":"2708_CR18","first-page":"93","volume":"3","author":"P Yu","year":"2020","unstructured":"Yu, P. et al. Age-related rhesus macaque models of COVID-19. Animal Model. Exp. Med. 3, 93\u201397 (2020).","journal-title":"Exp. Med."},{"key":"2708_CR19","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41586-020-2324-7","volume":"585","author":"VJ Munster","year":"2020","unstructured":"Munster, V. J. et al. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. Nature 585, 268\u2013272 (2020).","journal-title":"Nature"},{"key":"2708_CR20","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1525-0016(03)00221-1","volume":"8","author":"LE Ostrowski","year":"2003","unstructured":"Ostrowski, L. E., Hutchins, J. R., Zakel, K. & O\u2019Neal, W. K. Targeting expression of a transgene to the airway surface epithelium using a ciliated cell-specific promoter. Mol. Ther. 8, 637\u2013645 (2003).","journal-title":"Mol. Ther."},{"key":"2708_CR21","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1073\/pnas.1517719113","volume":"113","author":"VD Menachery","year":"2016","unstructured":"Menachery, V. D. et al. SARS-like WIV1-CoV poised for human emergence. Proc. Natl Acad. Sci. USA 113, 3048\u20133053 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2708_CR22","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.cell.2020.05.042","volume":"182","author":"YJ Hou","year":"2020","unstructured":"Hou, Y. J. et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell 182, 429\u2013446 (2020).","journal-title":"Cell"},{"key":"2708_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03812-w","volume":"9","author":"K Abdi","year":"2018","unstructured":"Abdi, K. et al. Uncovering inherent cellular plasticity of multiciliated ependyma leading to ventricular wall transformation and hydrocephalus. Nat. Commun. 9, 1655 (2018).","journal-title":"Nat. Commun."},{"key":"2708_CR24","doi-asserted-by":"publisher","first-page":"e0131451","DOI":"10.1371\/journal.pone.0131451","volume":"10","author":"VD Menachery","year":"2015","unstructured":"Menachery, V. D., Gralinski, L. E., Baric, R. S. & Ferris, M. T. New metrics for evaluating viral respiratory pathogenesis. PLoS ONE 10, e0131451 (2015).","journal-title":"PLoS ONE"},{"key":"2708_CR25","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1371\/journal.ppat.0030005","volume":"3","author":"A Roberts","year":"2007","unstructured":"Roberts, A. et al. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB\/c mice. PLoS Pathog. 3, e5 (2007).","journal-title":"PLoS Pathog."},{"key":"2708_CR26","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/nm.3985","volume":"21","author":"VD Menachery","year":"2015","unstructured":"Menachery, V. D. et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 21, 1508\u20131513 (2015).","journal-title":"Nat. Med."},{"key":"2708_CR27","doi-asserted-by":"crossref","unstructured":"Wang, D. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. J. Am. Med. Assoc. (2020).","DOI":"10.1001\/jama.2020.1585"},{"key":"2708_CR28","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","volume":"14","author":"E de Wit","year":"2016","unstructured":"de Wit, E., van Doremalen, N., Falzarano, D. & Munster, V. J. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14, 523\u2013534 (2016).","journal-title":"Nat. Rev. Microbiol."},{"key":"2708_CR29","doi-asserted-by":"publisher","first-page":"5833","DOI":"10.1128\/JVI.79.9.5833-5838.2005","volume":"79","author":"A Roberts","year":"2005","unstructured":"Roberts, A. et al. Aged BALB\/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans. J. Virol. 79, 5833\u20135838 (2005).","journal-title":"J. Virol."},{"key":"2708_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/ni875","volume":"4","author":"SV Kotenko","year":"2003","unstructured":"Kotenko, S. V. et al. IFN-\u03bbs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4, 69\u201377 (2003).","journal-title":"Nat. Immunol."},{"key":"2708_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/ni873","volume":"4","author":"P Sheppard","year":"2003","unstructured":"Sheppard, P. et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4, 63\u201368 (2003).","journal-title":"Nat. Immunol."},{"key":"2708_CR32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.coviro.2017.04.004","volume":"24","author":"M Elazar","year":"2017","unstructured":"Elazar, M. & Glenn, J. S. Emerging concepts for the treatment of hepatitis delta. Curr. Opin. Virol. 24, 55\u201359 (2017).","journal-title":"Curr. Opin. Virol."},{"key":"2708_CR33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215\u2013220 (2020).","journal-title":"Nature"},{"key":"2708_CR34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","volume":"581","author":"J Shang","year":"2020","unstructured":"Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221\u2013224 (2020).","journal-title":"Nature"},{"key":"2708_CR35","doi-asserted-by":"crossref","unstructured":"Felgenhauer, U. et al. Inhibition of SARS-CoV-2 by type I and type III interferons. J. Biol. Chem. jbc.AC120.013788 (2020).","DOI":"10.1074\/jbc.AC120.013788"},{"key":"2708_CR36","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.jhep.2014.07.022","volume":"61","author":"AJ Muir","year":"2014","unstructured":"Muir, A. J. et al. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J. Hepatol. 61, 1238\u20131246 (2014).","journal-title":"J. Hepatol."},{"key":"2708_CR37","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.jhep.2015.12.018","volume":"64","author":"HLY Chan","year":"2016","unstructured":"Chan, H. L. Y. et al. Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). J. Hepatol. 64, 1011\u20131019 (2016).","journal-title":"J. Hepatol."},{"key":"2708_CR38","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.antiviral.2017.01.012","volume":"140","author":"L Li","year":"2017","unstructured":"Li, L. et al. IFN-lambda preferably inhibits PEDV infection of porcine intestinal epithelial cells compared with IFN-alpha. Antiviral Res. 140, 76\u201382 (2017).","journal-title":"Antiviral Res."},{"key":"2708_CR39","doi-asserted-by":"publisher","first-page":"5670","DOI":"10.1128\/JVI.00272-10","volume":"84","author":"M Mordstein","year":"2010","unstructured":"Mordstein, M. et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J. Virol. 84, 5670\u20135677 (2010).","journal-title":"J. Virol."},{"key":"2708_CR40","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1086\/651022","volume":"201","author":"B Rockx","year":"2010","unstructured":"Rockx, B. et al. Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus. J. Infect. Dis. 201, 946\u2013955 (2010).","journal-title":"J. Infect. Dis."},{"key":"2708_CR41","doi-asserted-by":"publisher","first-page":"13769","DOI":"10.1128\/JVI.02232-14","volume":"88","author":"J Sui","year":"2014","unstructured":"Sui, J. et al. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness. J. Virol. 88, 13769\u201313780 (2014).","journal-title":"J. Virol."},{"key":"2708_CR42","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1128\/JVI.02377-07","volume":"82","author":"B Rockx","year":"2008","unstructured":"Rockx, B. et al. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. J. Virol. 82, 3220\u20133235 (2008).","journal-title":"J. Virol."},{"key":"2708_CR43","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","volume":"584","author":"SJ Zost","year":"2020","unstructured":"Zost, S. J. et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584, 443\u2013449 (2020).","journal-title":"Nature"},{"key":"2708_CR44","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1128\/JVI.02012-06","volume":"81","author":"PB McCray Jr","year":"2007","unstructured":"McCray, P. B. Jr et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 81, 813\u2013821 (2007).","journal-title":"J. Virol."},{"key":"2708_CR45","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1126\/science.1116480","volume":"309","author":"F Li","year":"2005","unstructured":"Li, F., Li, W., Farzan, M. & Harrison, S. C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309, 1864\u20131868 (2005).","journal-title":"Science"},{"key":"2708_CR46","doi-asserted-by":"publisher","first-page":"12995","DOI":"10.1073\/pnas.1735582100","volume":"100","author":"B Yount","year":"2003","unstructured":"Yount, B. et al. Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc. Natl Acad. Sci. USA 100, 12995\u201313000 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2708_CR47","doi-asserted-by":"publisher","first-page":"16157","DOI":"10.1073\/pnas.1311542110","volume":"110","author":"T Scobey","year":"2013","unstructured":"Scobey, T. et al. Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc. Natl Acad. Sci. USA 110, 16157\u201316162 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2708_CR48","doi-asserted-by":"publisher","first-page":"e00027","DOI":"10.1128\/JVI.00027-18","volume":"92","author":"S Agnihothram","year":"2018","unstructured":"Agnihothram, S. et al. Development of a broadly accessible Venezuelan equine encephalitis virus replicon particle vaccine platform. J. Virol. 92, e00027-18 (2018).","journal-title":"J. Virol."},{"key":"2708_CR49","first-page":"183","volume":"107","author":"ML Fulcher","year":"2005","unstructured":"Fulcher, M. L., Gabriel, S., Burns, K. A., Yankaskas, J. R. & Randell, S. H. Well-differentiated human airway epithelial cell cultures. Methods Mol. Med. 107, 183\u2013206 (2005).","journal-title":"Methods Mol. Med."},{"key":"2708_CR50","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.15252\/emmm.201606413","volume":"8","author":"S Davidson","year":"2016","unstructured":"Davidson, S. et al. IFN\u03bb is a potent anti-influenza therapeutic without the inflammatory side effects of IFN\u03b1 treatment. EMBO Mol. Med. 8, 1099\u20131112 (2016).","journal-title":"EMBO Mol. Med."}],"updated-by":[{"DOI":"10.1038\/s41586-020-03107-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000}}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-020-2708-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-020-2708-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-020-2708-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T07:04:15Z","timestamp":1696575855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-020-2708-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,27]]},"references-count":50,"journal-issue":{"issue":"7830","published-print":{"date-parts":[[2020,10,22]]}},"alternative-id":["2708"],"URL":"https:\/\/doi.org\/10.1038\/s41586-020-2708-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.05.06.081497","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,27]]},"assertion":[{"value":"6 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published: https:\/\/doi.org\/10.1038\/s41586-020-03107-5","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.D.B and I.C.C. are employees, and J.S.G is the founder and a board member of, Eiger BioPharmaceuticals, Inc., which produces peg-IFN-\u03bb1.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}